RT Journal
A1 Stone GW, Brener SJ, Gibson C
T1 ABciximab vs thrombectomy for reperfusion in myocardial infarction—reply
JF JAMA
JO JAMA
YR 2012
FD August 8
VO 308
IS 6
SP 565
OP 567
DO 10.1001/jama.2012.8167
UL http://dx.doi.org/10.1001/jama.2012.8167
AB 
In Reply: Drs Kikkert and Henriques requested information regarding outcomes in the INFUSE-AMI trial according to the presence of diabetes mellitus, specifically in regard to the results of manual thrombus aspiration. The randomized European and Australian Multicenter Evaluative Research on Atrial Fibrillation—Dofetilide (EMERALD) trial (N = 510) previously reported that myocardial perfusion was impaired in patients with diabetes (n = 65) vs those without diabetes after coronary intervention in patients with ST-segment elevation myocardial infarction.1 Conversely, the much larger Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial (N = 3265) found that there were no significant differences in the rates of thrombolysis in myocardial infarction flow or myocardial blush grade after PCI in patients with diabetes (n = 533) vs without diabetes.2